Prophylaxis In Hereditary Angioedema Type I And Ii Therapeutics
1. Orladeyo patent expiration
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and ped...
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(9 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US12116346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US12344585 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
|
US12344585 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11618733 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12116346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11117867 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11708333 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11230530 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10125102 (Pediatric) | BIOCRYST | NA |
Oct, 2035
(9 years from now) | |
|
US10689346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10662160 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US10329260 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 03, 2028 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 04 June, 2027
Market Authorisation Date: 03 December, 2020
Dosage: CAPSULE
More Information on Dosage
ORLADEYO family patents
